Pavilion Health Today
Supporting healthcare professionals to deliver the best patient care

Sarcopenia and amino acids

Sarcopenia is emerging as an important phenomenon in the older population and in future, regular screening may allow us to deliver interventions that could improve important functional outcomes associated with the condition.

First published January 2016, updated March 2022   Sarcopenia is a syndrome characterised by progressive and generalised loss of skeletal muscle mass and strength with a risk of adverse outcomes such as physical disability, poor quality of life and death.1 True prevalence in certain population groups is unknown, but a systematic review on the prevalence of sarcopenia by the European Working Group on Sarcopenia2 (EWGSOP) found the prevalence of sarcopenia to be 1€“29% in community dwelling populations, 14€“33% in long-term care populations and 10% in one acute care population.  The EWGSOP has recommended two criteria for identifying sarcopenia: low muscle


This content is restricted to members of Pavilion Health Today. If you are an existing user, please log in. New users may register for free below.

Existing Users Log In
New User Registration
*Required field

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read more ...

Privacy & Cookies Policy